BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferraro S, Bussetti M, Panteghini M. Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clin Chem 2021;67:602-9. [PMID: 33619518 DOI: 10.1093/clinchem/hvab002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen W, Wu S, Li G, Duan X, Sun X, Li S, Zhao Y, Gu D, Zeng G, Liu H. Accurate diagnosis of prostate cancer with CRISPR-based nucleic acid test strip by simultaneously identifying PCA3 and KLK3 genes. Biosensors and Bioelectronics 2023;220:114854. [DOI: 10.1016/j.bios.2022.114854] [Reference Citation Analysis]
2 Ferraro S, Cereda C, Zuccotti G, Biganzoli EM. Critical appraisal of “choosing which in-hospital laboratory tests to target for intervention: a scoping review”. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-1164] [Reference Citation Analysis]
3 Taheri M, Safarzadeh A, Hussen BM, Ghafouri-fard S, Baniahmad A. LncRNA/miRNA/mRNA Network Introduces Novel Biomarkers in Prostate Cancer. Cells 2022;11:3776. [DOI: 10.3390/cells11233776] [Reference Citation Analysis]
4 Podolsky E, Hudek N, Mccudden C, Presseau J, Yanikomeroglu S, Brouwers M, Brehaut JC. Choosing which in-hospital laboratory tests to target for intervention: a scoping review. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-0910] [Reference Citation Analysis]
5 Makhneva E, Sklenárová D, Brandmeier JC, Hlaváček A, Gorris HH, Skládal P, Farka Z. Influence of Label and Solid Support on the Performance of Heterogeneous Immunoassays. Anal Chem 2022. [DOI: 10.1021/acs.analchem.2c03543] [Reference Citation Analysis]
6 Agrawal R, Dey A, Datta S, Nassar A, Grubb W, Traughber B, Biswas T, Ove R, Podder T. Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database. Cancers 2022;14:5503. [DOI: 10.3390/cancers14225503] [Reference Citation Analysis]
7 Ferraro S, Biganzoli G, Bussetti M, Castaldi S, Biganzoli EM, Plebani M. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-0874] [Reference Citation Analysis]
8 Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, Del Giudice F, Sciarra A, Mariotti G, Gentilucci A. Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review. IJMS 2022;23:11501. [DOI: 10.3390/ijms231911501] [Reference Citation Analysis]
9 Satir A, Demirci H. Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.09.007] [Reference Citation Analysis]
10 Lumbreras B, Parker LA, Alonso-coello P, Mira-bernabeu J, Gómez-pérez L, Caballero-romeu JP, Pertusa-martínez S, Cebrián-cuenca A, Moral-peláez I, López-garrigós M, Canelo-aybar C, Ronda E, Guilabert M, Prieto-gonzález A, Hernández-aguado I. PROSHADE Protocol: Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study. IJERPH 2022;19:8904. [DOI: 10.3390/ijerph19158904] [Reference Citation Analysis]
11 Huang Z, Xie X, Xu B, Liu R, Hu J, Lv Y. Standard-free single magnetic bead evaluation: a stable nanoplatform for prostate disease differentiation. Chem Sci 2022;13:6270-5. [PMID: 35733887 DOI: 10.1039/d2sc00928e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zheng Y, Wang J, Chen G, Wang M, Chen T, Ke Q, Huang Y, Cai F, Huang R, Fan C. DNA walker-amplified signal-on electrochemical aptasensors for prostate-specific antigen coupling with two hairpin DNA probe-based hybridization reaction. Analyst 2022;147:1923-30. [PMID: 35384954 DOI: 10.1039/d2an00327a] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Ferraro S, Biganzoli EM. Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality. BJU Int 2022;129:418. [PMID: 35297160 DOI: 10.1111/bju.15611] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ferraro S, Biganzoli EM, Plebani M. Reply to: Spurious results for total and free prostate-specific antigen (PSA); sometimes really "a riddle wrapped in a mystery inside an enigma". Clin Chem Lab Med 2022. [PMID: 35258238 DOI: 10.1515/cclm-2022-0088] [Reference Citation Analysis]
15 Ferraro S, Biganzoli EM, Castaldi S, Plebani M. Health Technology Assessment to assess value of biomarkers in the decision-making process. Clin Chem Lab Med 2022. [PMID: 35245972 DOI: 10.1515/cclm-2021-1291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Popiołek A, Brzoszczyk B, Jarzemski P, Chyrek-Tomaszewska A, Wieczór R, Borkowska A, Bieliński M. Prostate-Specific Antigen and Testosterone Levels as Biochemical Indicators of Cognitive Function in Prostate Cancer Survivors and the Role of Diabetes. J Clin Med 2021;10:5307. [PMID: 34830590 DOI: 10.3390/jcm10225307] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Ferraro S, Biganzoli EM. The clinical value of assessing the inter-method bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med 2021. [PMID: 34751521 DOI: 10.1515/cclm-2021-1125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ferraro S, Rossi RS, Biganzoli EM. Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10. Cancer 2021. [PMID: 34297849 DOI: 10.1002/cncr.33811] [Reference Citation Analysis]
19 Ferraro S, Bussetti M, Bassani N, Rossi RS, Incarbone GP, Bianchi F, Maggioni M, Runza L, Ceriotti F, Panteghini M. Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers (Basel) 2021;13:3381. [PMID: 34298597 DOI: 10.3390/cancers13143381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]